ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "adjuvant arthritis"

  • Abstract Number: 986 • 2019 ACR/ARP Annual Meeting

    Tofacitinib Enhanced Cerebral Brain-derived Neurotrophic Factor Levelsin a Rat Model of Rheumatoid Arthritis

    Aurore Quirié 1, Clément PRATI 2, Daniel WENDLING3, Perle Totoson 4, Céline Demougeot 4 and Christine Marie 1, 1Inserm U1093, Action, cognition et plasticité sensorimotrice, F-21000 Dijon, France, Dijon, France, 2University Teaching Hospital (CHRU), Besançon, France, 3Rheumatology, University Teaching Hospital (CHRU), Besançon, France, 4PEPITE EA4267, Univ. Bourgogne Franche-Comté, F-25000 Besançon, France, BESANCON, France

    Background/Purpose: Cognitive dysfunction including depression-like symptoms is a frequent comorbidity of rheumatoid arthritis (RA). Recently, rats with adjuvant-induced arthritis (AIA) were found to exhibit reduced…
  • Abstract Number: 999 • 2019 ACR/ARP Annual Meeting

    Targeted Drug Delivery Using a Novel Joint-homing Peptide for Arthritis Therapy

    Rakeshchandra Meka1, Shivaprasad Venkatesha 1, Bodhraj Acharya 1 and Kamal Moudgil 1, 1University of Maryland School of Medicine and Baltimore VA Medical Center, Baltimore, Baltimore, MD

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic debilitating autoimmune disease characterized by inflammation of the synovial tissue of the joints, which if not controlled early…
  • Abstract Number: 86 • 2017 ACR/ARHP Annual Meeting

    Regulation of Interleukin-1β Signaling By Inhibition of O-Glc-Nacase in Rheumatoid Arthritis Synovial Fibroblasts

    Mahamudul Haque1, Anil Singh2, Kelly Kopczynski1 and Salahuddin Ahmed1, 1Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, 2Washington State University, College of Pharmacy, Spokane, WA

    Background/Purpose: O-GlcNAcylation is an important post-translational modification of nuclear and cytosolic proteins involved in the cytokine signaling networks. Studies show both pro- and anti-inflammatory roles…
  • Abstract Number: 389 • 2017 ACR/ARHP Annual Meeting

    S-110483 a New Potent EP4 Receptor Antagonist with Immunomodulatory and Analgesic Activities

    Takashi Maeda1, Toshitaka Ochiai2, Toshie Nagayasu-Tanaka1, Yuta Morisaki1, Haruka Takizawa1, Seiji Ishihara1, Shigeo Kurokawa1, Kiyoharu Ukai1 and Masahiro Suda1, 1Pharmacology Department, Kaken Pharmaceutical Co., LTD, Kyoto, Japan, 2Kaken Pharmaceutical Co., LTD, Kyoto, Japan

    Background/Purpose: Prostaglandin (PG) E2 is known to enhance the expansion of T helper 17 (Th17) cell population via EP4 receptor (EP4) in the early phase…
  • Abstract Number: 390 • 2017 ACR/ARHP Annual Meeting

    S-110483, a Novel and Selective EP4 Receptor Antagonist with Anti-Bone Destruction Activities

    Toshitaka Ochiai1, Takashi Maeda2, Toshie Nagayasu-Tanaka2, Jun Anzai1, Daiki Kato1, Yuta Morisaki2, Kiyoharu Ukai2 and Masahiro Suda2, 1Kaken Pharmaceutical Co., LTD, Kyoto, Japan, 2Pharmacology Department, Kaken Pharmaceutical Co., LTD, Kyoto, Japan

    Background/Purpose: S-110483 is our novel potent and selective EP4 receptor (EP4) antagonist. In addition to the well-known fact that EP4 antagonists have anti-inflammatory effects, it…
  • Abstract Number: 962 • 2017 ACR/ARHP Annual Meeting

    Role of Syndecans in Cytokine Mediated Inflammation in Rheumatoid Arthritis Synovial Fibroblasts

    Solomon Agere1, Nahid Akhtar1, David Fox2 and Salahuddin Ahmed1, 1Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, 2Department of Medicine [Division of Rheumatology], University of Michigan Medical System, Ann Arbor, MI

    Background/Purpose: Syndecans (SDCs) are type-I transmembrane proteoglycans that prominently interact with heparan sulfate, extracellular matrix (ECM) components and glycoproteins. The present study was carried out…
  • Abstract Number: 582 • 2016 ACR/ARHP Annual Meeting

    ACPA Induce Pathogenic Cytokines Expression in PBMC of ACPA+-RA Patients and Inhibition of Its Effect By Cit-ME a Synthetic Citrullinated Peptide

    Smadar Gertel1, Gidi Karmon2, Eszter Szarka3, , Esther Houri-Levi4, Edna mozes5, Yehuda Shoenfeld4 and Howard Amital6,7, 1Sheba Medical Center, Zabludowicz Center for Autoimmune Diseases, affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Ramat Gan, Israel, 2Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel, 3Department of Immunology,, Eötvös Loránd University, Budapest,, Budapest, Hungary, 4Zabludowicz Center For Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel, Ramat-Gan, Israel, 5Department of Immunology,, The Weizmann Institute of Science, Rehovot, Israel., Rehovot, Israel, 6Department of Medicine B, Center for Autoimmune Diseases, Sheba Medical Center, Tel-hashomer, Israel, 7Department of Internal Medicine 'D', Sackler Faculty of Medicine, Tel-Aviv University, Kfar-Saba, Israel

     ACPA induce pathogenic cytokines expression in PBMC of ACPA+-RA patients and inhibition of its effect by Cit-ME a synthetic citrullinated peptide.Smadar Gertel1, Gidi Karmon1, Eszter…
  • Abstract Number: 480 • 2016 ACR/ARHP Annual Meeting

    Local Cryotherapy Down-Regulates Local and Systemic IL-6/IL-17 Pathway with No Effect on TNF-α in Adjuvant-Induced Arthritis

    Xavier Guillot1,2, Hélène Martin1, Katy Maguin-Gaté1, Stéphanie Py3, Céline Demougeot1, Daniel Wendling4 and Nicolas Tordi5, 1EA 4267 FDE, FHU INCREASE, Université de Bourgogne Franche-Comté, Besançon, France, 2EA 4267 FDE, FHU INCREASE, Bourgogne Franche-Comté University, Besançon, France, 3INSERM-CIC 1431, Besançon University Hospital, Besançon, France, Besançon, France, 4Rheumatology, Besançon university hospital, Besançon, France, 5EA 4267 FDE, FHU INCREASE,, Bourgogne Franche-Comté University, Besançon, France

    Background/Purpose: Cryotherapy is widely and empirically used in an adjuvant and symptomatic setting in inflammatory rheumatic diseases, with a low level of evidence [1]. The aim…
  • Abstract Number: 483 • 2016 ACR/ARHP Annual Meeting

    Non-Steroidal Anti-Inflammatory Drugs Are More Beneficial Than Anti-Tnfα Drugs on the Radiographic Damage in Arthritis: A Study in Adjuvant Induced Arthritis

    Frank Verhoeven1, Clément Prati2, Perle Totoson1, Romani Bordy3, Daniel Wendling4 and Céline Demougeot1, 1EA 4267 FDE, FHU INCREASE, Université de Bourgogne Franche-Comté, Besançon, France, 2FDE EA4267, FHU INCREASE, Bourgogne Franche-Comté University, Besançon, France, 3EA 4267 FDE, FHU increase, BESANCON, France, 4Service de Rhumatologie, CHU Jean Minjoz, Besancon, France

    Background/Purpose: The management of the chronic inflammatory rheumatisms has dramatically evolved in the last decade with a concept of “treat to target”. The theory of…
  • Abstract Number: 2360 • 2014 ACR/ARHP Annual Meeting

    Glucocorticoids and Vascular Function in Arthritis: Benefic or Deleterious Effects? Study in Rat

    Frank Verhoeven1, Katy Maguin-Gaté2, Perle Totoson3, Daniel Wendling4 and Céline Demougeot5, 1Rheumatology, CHU jean Minjoz, Besançon, France, 2EA 4267 « Fonctions et Dysfonctions Epithéliales » , Faculté de Médecine-Pharmacie, Besançon, France, 3UFR Sciences Médicales et Pharmaceutiques, EA 4267 "Fonctions et Dysfonctions Epithéliales", besançon, France, 4Service de Rhumatologie, CHU J Minjoz, Besancon, France, 5UFR Sciences Médicales et Pharmaceutiques, EA 4267 "Fonctions et Dysfonctions Epithéliales", Besançon, France

    Background/Purpose: Rheumatoid Arthritis (RA) is associated to an increase of cardiovascular (CV) risk explained in part by an accelerated atherosclerosis as a consequence of endothelial…
  • Abstract Number: 1499 • 2014 ACR/ARHP Annual Meeting

    Characterization of ABT-494, a Second Generation Jak1 Selective Inhibitor

    Candace Graff1, Annette Schwartz1, Jeffrey Voss2, Neil Wishart3, Lisa Olson1, Jonathon George3, Deborah Hyland3 and Heidi Camp4, 1AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, 2Immunology, AbbVie Pharmaceuticals, Worcester, MA, 3Abbvie Pharmaceuticals, worcester, MA, 41101 Oak Street, Abbvie, Winnetka, IL

    Background/Purpose  Jak kinase blockade can effectively manage rheumatoid arthritis (RA) and in some cases achieve remission. However, first generation Jak inhibitors have not met expectations…
  • Abstract Number: 330 • 2014 ACR/ARHP Annual Meeting

    Prolactin Reduces Bone Erosion in Adjuvant-Induced Arthritis

    Maria G. Ledesma-Colunga, Norma Adan, Ana L. Reyes-Lopez, Fernando Lopez-Barrera, Gonzalo Martinez de la Escalera and Carmen Clapp, Institute of Neurobiology, National University of Mexico (UNAM), Queretaro, Mexico

    Background/Purpose Bone erosion is an important feature of rheumatoid arthritis (RA) that frequently results in lifelong crippling. The receptor activator of NFkB ligand (RANKL)/osteoprotegerin (OPG)/RANK…
  • Abstract Number: 2819 • 2013 ACR/ARHP Annual Meeting

    Administration Of a Multi-Epitope Citrullinated Peptide Attuneuates adjuvant  Induced Arthritis In Rats Via Induction Of Immune Tolerance

    Howard Amital1, Smadar Gertel2 and Yehuda Shoenfeld3, 1The Zabludowicz Center For Autoimmune Diseases, and Department of Medicine 'B',, Sheba Medical Center,Tel-Hashomer, Tel-Aviv University, Tel-hashomer, Israel, 2The Zabludowicz Center For Autoimmune Diseases, and Department of Medicine 'B', Sheba Medical Center, Tel-Hashomer, Israel, 3Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Affiliated to Sackler Faculty of Medicine, Tel-Aviv University,Tel-Aviv, Tel-Aviv, Israel

    Background/Purpose: Antigen-induced peripheral tolerance is a potentially efficient and specific therapeutic approach to attenuate autoimmunity. Citrullinated peptides are major targets of disease-specific autoantibodies in Rheumatoid…
  • Abstract Number: 2222 • 2013 ACR/ARHP Annual Meeting

    Positive Allosteric Modulation Of The Adenosine A2a Receptor Alters Inflammatory Cytokine Production and Alleviates Chronic Arthritis In Rats

    Ajith A. Welihinda, Jordan A. Mechanic and Edward P. Amento, Molecular Medicine Research Institute, Sunnyvale, CA

    Background/Purpose: Rheumatoid arthritis is a chronic systemic autoimmune disease characterized by inflammation and joint destruction; a consequence of which is the high local concentration of…
  • Abstract Number: 1302 • 2013 ACR/ARHP Annual Meeting

    Application of Cytostatic Agent Kinesin Eg5 Inhibitor Litronesib (KF89617) On Rat Adjuvant-Induced Arthritis and Mouse Type II Collagen-Induced Arthritis

    Ichiro Miki1 and Masako Uchii2, 1Fuji Research Park, Kyowa Hakko Kirin, Co., Ltd., Shizuoka, Japan, 2Fuji Research Park, Kyowa Hakko Kirin Co., Ltd., Shizuoka, Japan

    Background/Purpose:   Kinesins are family of motor proteins that are involved in mitosis and intracellular transport of vesicles and organelles. The mitotic kinesin, Eg5, acts…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology